Figures & data
Table 1 Baseline and disease characteristics in patients receiving MTX, MTX + INF, and MTX + ETA
Table 2 Incidence proportion of elevated liver enzymes within 8 years in visit level in patients receiving MTX, MTX + INF, and MTX + ETA
Table 3 Incidence proportion of elevated liver enzyme within 8 years in period level
Table 4 Effect of MTX + INF/ETA on ALT and AST changes unadjusted and adjusted by MTX dose
Table 5 Effect of ETA + MTX and INF + MTX on ALT and AST changes adjusted by MTX dose
Figure 1 Mean trend of ALT in MTX therapy period vs period of adding ETA or INF.
Abbreviations: ALT, alanine aminotransferase; ETA, etanercept; INF, infliximab; MTX, methotrexate.
Figure 2 Mean trend of AST in MTX therapy period vs period of adding ETA or INF.
Abbreviations: AST, aspartate aminotransferase; ETA, etanercept; INF, infliximab; MTX, methotrexate.
